SHP656 / Synchronicity Pharma - LARVOL DELTA

A compound targeting the circadian clock protein CRY2 enhances therapeutic efficacy of bevacizumab in a colorectal cancer (CRC) xenograft model (AACR 2024) - "In this study, we evaluated whether CRY stabilizers SHP656 and SHP1705 in combination with bevacizumab can synergistically enhance anti-tumor effect in CRC mouse models. In vitro tube formation assay was performed with HUVECs cells to investigate the effect of CRY stabilizer on tube formation. Our study shows that CRY stabilizers in combination with bevacizumab significantly enhances anti-tumor efficacy in CRC mouse models. Although mechanism of action of SHP compounds on angiogenesis pathway still needs further investigation, these findings may support development of novel treatment strategies modulating circadian clock to overcome bevacizumab resistance in CRC patients."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • ARNTL • BMAL1

New Biochemical Approaches for Treatment of Glioblastoma. (PubMed, J Biol Chem) - "Even with the standard-of-care consisting of surgery, radiotherapy, plus temozolomide (TMZ) treatment, the median survival time is around 12 months. Recently, several new chemotherapeutic approaches have been developed that target DNA or the circadian clock for treating glioblastoma. Here after briefly reviewing the standard of care, TMZ, we summarize the mechanistic bases of these new approaches and their potential for improving treatment of glioblastoma and other brain tumors."

Journal • Review • Brain Cancer • Glioblastoma • Oncology • Solid Tumor